Loading patent…
AssigneePontificia Universidad Catolica De Chile
InventorsSusan Marcela Bueno Ramirez, Alexis Mikes Kalergis Parra, Christian Palavecino Beaumont
Estimating the term…
The present invention relates to an immunogenic formulation to be used in mammals against human Metapneumovirus (hMPV), consisting of a lyophilisate of 1×109 ufc/ml of recombinant BCG that expresses the viral protein P of hMPV (of genogroups A1, A2, B1 and B2). The vaccine is derived from the full or partial product of the P gene of hMPV, capable of being used, stabilised and administered in solution without requiring adjuvants. The preparation can also contain combinations of the aforementioned formulations. The formulation is stabilised by means of lyophilisation (conservation range of between 4° C. and 8° C.) in order to be subsequently reconstituted in an adjuvant-free saline solution prior to use.
An immunogenic formulation that confers protection against infection by human metapneumovirus (hMPV) and/or attenuates the pathogenicity of the hMPV, wherein the formulation comprises one or more recombinant attenuated Mycobacterium strain in an amount that ranges from 104 to 109 bacteria CFU/dose per strain, wherein each strain expresses an hMPV P-protein or an immunogenic fragment thereof in a pharmacologically appropriate saline buffer.
A lyophilized or freeze-dried formulation comprising one or more recombinant attenuated Mycobacterium strain in an amount that ranges from 104 to 109 bacteria CFU/dose per strain, wherein each strain expresses a hMPV protein or an immunogenic fragment thereof.
Dependencies are inferred from the claim text.